“The Pelvic Floor Disorders Diagnostics and Treatment: Marc Beer’s Renovia. “

The background of Marc Beer.

Marc Beer has over 20 years of experience in biotechnology, diagnostics and pharmaceutical devices and services. He founded the Renovia pharmaceuticals in 2016, alongside Ramon Iglesias and, Yolanda Lorie. Renovia successfully closed a series A funding with a leading healthcare capital finance. Marc Beer has acquired his know in biopharmaceuticals development and commercialization of customized therapies for patients with extremely rare diseases. He also has experience in running public businesses in drug administration and distribution. In 2000, Marc Beer was the CEO of a biotechnology company focused on the collection, development, and preservation of umbilical cord blood stem cells. Within seven years, Marc Beer led the company into a robust and rapidly growing company. The company went public in a few years, had over 300 employees and was acquired in 2007 by PerkinElmer.

Marc Beer has held a number of positions in the pharmaceutical industry. While he was the CEO of Viacell, he also served as member of the board of directors of Erytech. Erytech is a publicly traded company that dealt in biopharmaceuticals. He also held a number of positions in Genzyme. He was also the Vice President of the global marketing team. In this position, he led the company to a commercial launching of a number of products addressing rare diseases affecting populations worldwide. Before Genzyme, he held a number of positions and roles in the marketing and sales of pharmaceuticals and diagnostic services and products. With his experience, Marc Beer has held a number of positions that we could go on about for a very long time. He was also a member of the Mass Life Science Board of the Commonwealth of Massachusetts among other recognitions.

Through Renovia, Marc Beer is leading in the development of products that deal with pelvic floor disorders with the Tuesday closing of 32 million dollars from the series B and a 10 million dollars in venture debt. The variety of disorders that the Boston-based biotech company is focusing on, in terms of diagnostic and therapeutic products production, related to the urinary incontinence. This disorder affects over 250 million women in the world. Learn more: https://people.equilar.com/bio/marc-beer-aegerion-pharmaceuticals-/salary/78453

The funding was drawn from a number of organizations that invest in healthcare based organization like the Longwood fund. The Longwood Fund joined the series B round which was led by the Missouri based Ascension ventures and the New York perceptive advisors. The organization has invested before with Renovia. The funding will go towards further developing and testing of four more therapeutic and diagnostic and the development of a new generation of Leva device. The company plans to combine sensor technology with and digital health platform to inform their clients on new treatment options and learn more of pelvic floor disorders.

Scott Rocklage Leading The Way In The FIght Against Muscular Dystrophy

Scott Rocklage and Expansion Therapeutics is committed to battling an assortment of genetic disorders and has now turned its attention to combatting the horrible effects of muscular dystrophy in adult patients. The company has designated $55.3 million that it that it was able to raise with the use of Series A financing to be used in the fight against the disease.


Scott Rocklage is a managing partner with 5AM Ventures which provided a significant portion of the funding for Expansion Therapeutics.


RNA is a molecule present within DNA which is converted into proteins and transferred through the body. At times, RNA can be said to become ‘toxic’ within the cells. When this happens a condition known as Myotonic dystrophy type one, the chief cause of muscular dystrophy in adults, is the result. A number of bodily functions are negatively affected by this condition including muscle and heart functions, the respiratory system, and the central nervous system.


In some instances, entire families are afflicted with DM1 and the effects have been observed to worsen with each generation. There is no current treatment known to the medical community that has proven effective at combatting DM1.


Expansion Therapeutics focuses its efforts on creating medications that directly addresses any corruption to the RNA. DM1 is part of a class of diseases known as expansion repeat disorders. These illnesses are hereditary and are passed down through the DNA. Expansion repeat disorders do not respond well to current medical practices.


About Scott Rocklage


Scott Rocklage works in senior management with 5AM Ventures. Rocklage began his preparations for over 30 years of healthcare management experience by attending the University of California at Berkley. After receiving his bachelor’s degree in chemistry, Rocklage moved on to the Massachusetts Institute of Technology where he received a Ph.D. in the same subject.


While studying at MIT, Rocklage performed research duties in the laboratory of Dr. Richard Schrock. Dr. Schrock was recognized for his work in the field of chemistry with a Nobel Prize in 2005.


Scott Rocklage joined 5AM Ventures in 2003 and would become managing partner for the firm a year later.


Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.